ResMed lifts dividend 10% and completes $1.4 billion buyback but flags softer fiscal 2027 outlook after ventilator recall

EarningsCorporate ActionRegulation
โดย Simply Wall St·US·Read original
Summary · why it matters

ResMed reported higher fourth-quarter and full-year sales and earnings, raised its quarterly dividend by 10% to US$0.66, and completed a US$1.40 billion share buyback program. Management issued a softer fiscal 2027 outlook tied to suspended Astral ventilator sales following an FDA Class 1 recall and ongoing cost pressures, with the ventilator suspension expected to create a US$75 million revenue headwind. The company’s narrative projects US$6.5 billion in revenue and US$1.8 billion in earnings by 2029, though some analysts had previously assumed revenue near US$6.8 billion and earnings near US$1.8 billion by that year.

Impact on stocks 1

Cloud & Digital Infrastructure▲ · 1 stocks
ResMed Inc
RMD
± MixedCapitalrelevance

Raises dividend and completes buyback (positive) but flags softer FY2027 outlook due to ventilator recall and cost pressures (negative).

© 2026 MarketDXNews